Standex International Stock Hits New 52-Week High (SXI)

NEW YORK ( TheStreet) -- Standex International Corporation (NYSE: SXI) hit a new 52-week high Thursday as it is currently trading at $39.18, above its previous 52-week high of $39.11 with 35,744 shares traded as of 12:10 p.m. ET. Average volume has been 66,600 shares over the past 30 days.

Standex International has a market cap of $462.3 million and is part of the industrial goods sector and industrial industry. Shares are up 24.5% year to date as of the close of trading on Wednesday.

Standex International Corporation manufactures and sells products and services for various industrial markets worldwide. The company has a P/E ratio of 12.8, below the average industrial industry P/E ratio of 13.1 and below the S&P 500 P/E ratio of 17.7.
  • Practice your SXI trading strategies and win cash in our stock game.

TheStreet Ratings rates Standex International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. You can view the full Standex International Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

null

More from Markets

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus